Skip to main content

Advertisement

Table 2 Treatment regimen composition and characteristics

From: Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada

Treatment Regimen
Intensive phase/Continuation phase
Total patients
(n = 165)a
6 to <9 Months (n, %)
 (H)RZE/(H)RE 8 (4.8)
 (H)RZE/(H)RZE 6 (3.6)
 (H) RZEQ/REQ 6 (3.6)
 Other 1 (0.2)
≥ 9 to ≤12 Months (n, %)
 (H)RZE/(H)RE 32 (19.4)
 (H)RZE/(H)RZE 35 (21.2)
 (H)RZE(Q)/(H)REQ 14 (8.5)
 (H)RZE(Q)/(H)RZEQ 10 (6.1)
 (H)RE/(H)RE 4 (2.4)
 Other 17 (10.3)
> 12 Months (n, %)
 (H)RZE/(H)RE 1 (0.2)
 (H)RZE/(H)RZE 6 (3.6)
 (H)RZE(Q)/(H)REQ 4 (2.4)
 Other 15 (9.1)
  1. I isoniazid, P pyrazinimide, R rifampin, E ethambutol, Q fluoroquinolone, S streptomycin
  2. a6 (3.6%) patients were on treatment for <6 months due to treatment non-completion or death